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Comparison of Bolus Only With Bolus
Plus Infusion of Bivalirudin in Patients
Undergoing Elective Percutaneous
Coronary Intervention: A Retrospective
Observational Study
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Abstract
Background: Anticoagulation therapy during percutaneous coronary intervention (PCI) has been the focus of numerous clinical
trials. Low-anticoagulant doses have been successfully used in patients undergoing elective PCI, a situation with low-thrombogenic
milieu. Objective: The purpose of the study was to evaluate the safety and efficacy of shorter duration of treatment with bivalirudin
in patients undergoing elective PCI and receiving optimal antiplatelet therapy. Methods: We compared patients undergoing PCI
who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus
of 0.75 þ 1.75 mg/kg per h for the duration of PCI; n ¼ 197) or a reduced bivalirudin dose (IV bolus of 0.75 mg/kg; n ¼ 200).
Results: Procedural success was obtained in 100% of cases. The primary end point (in-hospital death, acute myocardial infarction,
or need for urgent target vessel revascularization) did not differ between both the groups (6 patients [3%] in the conventional
dose group vs 5 patients [2.5%] in the reduced dose group). Major bleeding occurred in 1 patient in the conventional dose group
(P ¼ nonsignificant [NS]). Minor bleeding occurred in 4 patients (2%) in the conventional dose group vs 5 patients (2.5%) in the
reduced dose group (P ¼ NS) and was mainly due to bleeding at entry site. Conclusion: In patients undergoing elective PCI, using
bivalirudin as a bolus only dosing may be as effective and less costly when compared with bolus followed by an infusion for the
duration of the intervention. A larger study is needed to confirm our findings.
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Introduction
Percutaneous coronary intervention (PCI) results in plaque
rupture that increases the risk of thrombosis and ischemic com-
plications. PCI has dramatically improved because of innova-
tion in techniques, stents, and antiplatelet agents, but optimal
adjunctive antithrombotic treatment remains uncertain. The
central role of thrombin in thrombosis arising from plaque rup-
ture makes thrombin an essential target for pharmacotherapy.
Bivalirudin (Angiomax1) is a direct thrombin inhibitor that
has been extensively investigated in the prevention of thrombo-
sis during and shortly after PCI.1-7 In PCI, bivalirudin has pro-
vided similar antithrombotic protection as unfractionated
heparin (UH) with glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors
with significantly less major.1,4,6,7 The American College of
Cardiology and American Heart Association guidelines gave
bivalirudin a class I recommendation in PCI.8
Important theoretical advantages of bivalirudin over UH are
the lack of platelet-activating effect and lack of rebound effect
characterized by increased thrombin activity and myocardial
infarction (MI).9,10 A consistent finding across multiple
clinical studies of bivalirudin is the reduction in the rates of
bleeding without the loss of antithrombotic efficacy. Potential
cost benefits from the extensive use of bivalirudin include the
reduction in the use of GPIIb/IIIa inhibitors and rates of bleed-
ing. A further reduction in the cost can be achieved if an expen-
sive prolonged infusion could be avoided in low-risk patients
undergoing PCI. Bivalirudin comes in a 250-mg vial with an
average cost of $572 per vial.
More recent studies have asked whether anticoagulation is
necessary for low-risk elective PCI, when aggressive upstream
antiplatelet therapy is already in use.11-13 One study has
claimed that only minute doses of UH are needed during
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uncomplicated stent placement.14 We hypothesized that in low-
risk patients already receiving optimal antiplatelet therapy
prior to elective PCI, a bolus dose of 0.75 mg/kg bivalirudin
would be therapeutically equivalent to the same bolus dose fol-
lowed by an infusion of 1.75 mg/kg per h for the duration of the
PCI procedure. In this retrospective observational analysis of
major adverse cardiovascular events (MACEs) in patients
undergoing elective PCI, we compared the efficacy and safety
of bivalirudin bolus plus infusion against bolus only.
Methods
From our database at Huntsville Hospital, an 881-bed regional
referral center located in North Alabama, we retrospectively
identified low-risk patients undergoing elective PCI and com-
pared 2 groups of patients, 1 group received conventional biva-
lirudin dosing (IV bolus of 0.75 þ 1.75 mg/kg per h for the
duration of PCI) and another group received reduced bivaliru-
din dose (IV bolus of 0.75 mg/kg). The use of the reduced biva-
lirudin dose was left to the discretion of the operator. All
patients received 325 mg of aspirin and 300 to 600 mg of clo-
pidogrel at least 2 hours before the procedure. During PCI,
either abciximab or eptifibatide were given for procedural com-
plications, such as thrombus, distal embolization, slow flow, or
prolonged myocardial ischemia. Coronary stenting with either
bare-metal or drug-eluting stents, according to the choice of the
physician, was the preferred method of PCI. We excluded
patients who had acute coronary syndrome (ACS).
The primary end point was a composite of death, acuteMI, or
need for urgent target vessel revascularization occurring during
hospitalization. MI was defined as new Q waves on electrocar-
diogram or creatine kinase (CK) or Creatine Kinase Myocardial
Band (CK-MB) elevation3 times the upper limit of normal. In
addition, we assessed length of hospitalization post-PCI and
incidence of noncoronary artery bypass graft bleeding. Major
bleeding was defined as a drop in hemoglobin level to >4 g/
dL, overt bleeding with a drop in hemoglobin level to >3 g/
dL, a blood transfusion of2 units or retroperitoneal, intraocu-
lar, or intracranial hemorrhage. Minor bleeding was defined as
overt bleeding not meting criteria for major bleeding. Proce-
dural success was considered a <30% residual stenosis and
achieving a thrombolysis in MI (TIMI) flow grade of 3.
Statistical Analysis
All statistical analyses were done using the Statistical Package
for the Social Sciences (SPSS) software. Chi-square tests were
performed to evaluate the statistical association between the
patients who were given the conventional bivalirudin regimen
compared with the reduced regimen and the reported primary
end points or other related categorical variables. The t test were
performed for continuous variables. Results were statistically
significant when P  .05.
Results
Table 1 lists the baseline characteristics. A total of 197 patients
received conventional bivalirudin dose (group 1), while 200
patients received the reduced bivalirudin dose (group 2). Both
the groups were well matched in all baseline characteristics
except for the use of GPIIb/IIIa inhibitors. Eptifibatide and
abciximab, whose infusion was started in the catheterization
Table 1. Distribution of Patient Characteristics by Bivalirudin
Regimen
Group I
(bolus þ infusion)
Group II
(bolus only)
P
value
N 197 200
Age, years 62.2 + 12 61.5+ 12 NS
Males (%) 136 (69) 134 (67) NS
Previous MI (%) 58 (29.44) 62 (31) NS
Previous PCI (%) 63 (31.98) 70 (35) NS
Previous CABG (%) 34 (17.26) 39 (19.5) NS
HF (%) 27 (13.70) 20 (10) NS
HTN (%) 141 (71.57) 148 (74) NS
DM (%) 67 (34.01) 61 (30.5) NS
CrCl <40 mL/min (%) 6 (3) 7 (3.5) NS
Current smoker (%) 61 (30.96) 57 (28.5) NS
Eptifibatide (%) 51 (25.88) 74 (37)
Abciximab (%) 1 (0.51) 2 (1) .025
Device type (%) Balloon (3.6) Balloon (4.5) NS
Bare metal
stent (27.9)
Bare metal
stent (28)
Drug-eluting
stent (68.5)
Drug-eluting
stent (67.5)
Procedure duration
(min+ SD)
64 + 22 61+ 18 NS
Abbreviations: MI, myocardial infarction; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass grafting; HF, heart failure; HTN,
hypertension; DM, diabetes mellitus; CrCl, creatinine clearance; NS,
nonsignificant.
Table 2. Distribution of Primary End Points by Bivalirudin Regimen
Group I
(bolus þ infusion)
Group II
(bolus only) P value
Primary end points (%) 6 (3) 5 (2.5) NS
Periprocedural MI (%) 5 (2.54) 3 (1.5) NS
Death (%) 0 (0) 2 (1) NS
Urgent vessel
revascularization (%)
1 (0.51) 0 (0) NS
Abbreviations: MI, myocardial infarction; NS, nonsignificant.
Table 3. Distribution of Related Variables by Bivalirudin Regimen
Group I
(bolus þ infusion)
Group II
(bolus only) P value
Hospital stay post PCI, days 1.59 + 1.18 1.76+ 1.34 NS
CABG, n (%) 0 (0) 0 (0) -
Major bleeding, n (%) 1 (0.5) 0 (0) NS
Minor bleeding, n (%) 4 (2) 5 (2.5) NS
Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary
artery bypass grafting; NS, nonsignificant.
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laboratory, were used in 26% of patients in the conventional
dose group and 38% of patients in the reduced dose group
(P ¼ .025).
Procedural success was 100% in both the groups. The pri-
mary end point of the study did not differ between both the
groups (6 patients [3%] in the conventional dose group vs 5
patients [2.5%] in the reduced dose group; Table 2). There was
no significant difference in the rate of periprocedural MI among
patients treated with the conventional dose versus the reduced
dose bivalirudin (5 patients, 2.5% vs 3 patients, 1.5%; P ¼
NS). None of the patients died in the conventional dose group,
while 2 patients died in the reduced dose group (P ¼ NS). One
patient underwent urgent target vessel revascularization in the
conventional dose group while none in the reduced dose group
(P ¼ NS). Major bleeding occurred in 1 patient in the conven-
tional dose groupwhile none occurred in the reduced dose group
(P¼NS) and was due to intracranial hemorrhage. Minor bleed-
ing occurred in 4 patients (2%) in the conventional dose group
versus 5 patients (2.5%) in the reduced dose group (P¼NS) and
was mainly due to bleeding at entry site. Hospital stay did not
differ significantly between both the groups (Table 3).
Discussion
PCI is the most commonly performed invasive therapeutic car-
diac procedure and plays an important role in the treatment of
ischemic heart disease. Procedural anticoagulation therapy has
been the focus of numerous clinical trials. The REPLACE-2
trial (Randomized Evaluation of PCI Linking Angiomax to
Reduced Clinical Events) was conducted in the setting of cor-
onary stenting in a lower risk elective population. The study
randomized 6010 patients undergoing urgent or elective PCI
to either UH plus planned GPIIb/IIIa inhibitors or to bivalirudin
with provisional use of GPIIb/IIIa given only for procedural
complications.4 The primary end point was a 30-day incidence
of death, MI, urgent repeat revascularization, or in-hospital
major bleeding. Bivalirudin with provisional BPIIb/IIa inhibi-
tors was found to be statistically noninferior to UH plus
planned GPIIb/IIIa blockade and was associated with less
bleeding. Some clinical trials have suggested that in simple and
elective procedures, the use of anticoagulation is not crucial,
while some studies suggested that low-dose anticoagulant ther-
apy is as effective as full dose.11-15
Our study analyzed the outcomes in low-risk patients who
had been treated with 325 mg aspirin and a loading dose of
300 to 600 mg clopidogrel at least 2 hours before undergoing
elective PCI. The GPIIb/IIa was used for procedural complica-
tions. All patients received clopidogrel at a loading dose of at
least 300 mg prior to the procedure in order to achieve a high
degree of platelet inhibition by the time the coronary interven-
tion was performed.16,17 We compared the conventional biva-
lirudin dose with a reduced dose where the continuous
infusion was omitted. Our study did not find the differences
between the regimens in terms of in-hospital death, MI, or
urgent revascularization, nor in the individual end point com-
ponents. In addition, no differences were found between the
2 groups in major and minor bleeding, vascular entry site com-
plications, and length of hospital stay after PCI. It is note-
worthy that 2 patients died in the bolus only group while
none in the bolus þ infusion group, which was not statistically
significant. However, a larger sample size is needed to rule out
any potential difference related to death.
We expected the reduced dose arm to experience a lower
incidence of bleeding. However, the similar rate of bleeding
between both the groups could be explained by the small sam-
ple size or the more frequent use of GPIIb/IIa inhibitors in the
reduced dose arm (26% vs 38%).
The results of this study are consistent with those of lower
anticoagulant dosing in low-risk patients undergoing PCI.
Godon et al used a single bolus dose of UH of 30 U/kg in 418
patients undergoing PCI, excluding those with recent MI or left
main stem disease and concluded that the use of this low-dose
UH appears to be safe and effective, allows faster mobilization,
and earlier hospital discharge.14 In addition, Choussant et al
examined a reduced dose (0.5 mg/kg) of enoxaparin in elective
PCI patients and concluded that the dose appears to be safe and
effective.15 Bivalirudin has a half-life of 25 minutes.18
The study has several limitations. First, it is monocentric,
not randomized, retrospective, and is of a small sample size.
Second, we did not follow patients after hospital discharge to
assess the incidence of MACE. Finally, more patients in the
reduced dose group received GPIIb/IIa inhibitors.
It has to be noted that all of our patients underwent elective
PCI to treat chronic artery disease, and hence, the results of this
study may not be applicable to patients with ACS, a situation
with high thrombogenic milieu.
Conclusion
In patients undergoing elective PCI, using bivalirudin as a bolus
only dosing may be as effective and less costly when compared
with bolus followed by an infusion for the duration of the inter-
vention. A larger study is needed to confirm our findings.
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